Sight Sciences, Inc. (NASDAQ:SGHT) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its position in Sight Sciences, Inc. (NASDAQ:SGHT) by 47.6% during the fourth quarter, HoldingsChannel reports. The firm owned 17,622 shares of the company’s stock after buying an additional 5,681 shares during the quarter. SG Americas Securities LLC’s holdings in Sight Sciences were worth $64,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. KCK LTD. purchased a new stake in shares of Sight Sciences in the 4th quarter valued at approximately $15,925,000. Barclays PLC increased its position in shares of Sight Sciences by 317.4% in the 3rd quarter. Barclays PLC now owns 50,300 shares of the company’s stock valued at $317,000 after purchasing an additional 38,248 shares during the last quarter. Millrace Asset Group Inc. purchased a new stake in shares of Sight Sciences in the 3rd quarter valued at approximately $874,000. Geode Capital Management LLC increased its position in shares of Sight Sciences by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock valued at $4,941,000 after purchasing an additional 12,709 shares during the last quarter. Finally, State Street Corp increased its position in shares of Sight Sciences by 17.4% in the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after purchasing an additional 95,843 shares during the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Sight Sciences

In other Sight Sciences news, CEO Paul Badawi sold 12,236 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.60, for a total transaction of $44,049.60. Following the transaction, the chief executive officer now directly owns 5,713,197 shares of the company’s stock, valued at approximately $20,567,509.20. This trade represents a 0.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have purchased 15,000 shares of company stock valued at $58,232 and have sold 63,014 shares valued at $197,295. Insiders own 28.90% of the company’s stock.

Sight Sciences Trading Up 7.0 %

NASDAQ SGHT opened at $2.74 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The firm’s fifty day moving average price is $3.24 and its 200 day moving average price is $4.82. The company has a market capitalization of $139.08 million, a price-to-earnings ratio of -2.69 and a beta of 2.52. Sight Sciences, Inc. has a 12 month low of $2.50 and a 12 month high of $8.45.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. UBS Group dropped their price objective on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating on the stock in a research report on Monday, January 27th. Morgan Stanley dropped their price objective on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, November 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research report on Tuesday, January 14th. Piper Sandler reaffirmed a “neutral” rating and issued a $5.50 target price (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Finally, Lake Street Capital dropped their target price on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Wednesday, January 15th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.68.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.